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ABSTRACT
The dysfunction in a number of inherited cardiac and
skeletal myopathies is primarily due to an altered ability
of myoﬁlaments to generate force and motion. Despite
this crucial knowledge, there are, currently, no effective
therapeutic interventions for these diseases. In this short
review, we discuss recent ﬁndings giving strong evidence
that genetically or pharmacologically modulating one of
the myoﬁlament proteins, myosin, could alleviate the
muscle pathology. This should constitute a research and
clinical priority.
In cardiac and skeletal muscles, the contractile
machinery consists of assemblies of interdigitating
myoﬁlaments integrated in highly ordered entities
termed sarcomeres.1 Mutations in genes encoding
proteins located in the sarcomeres have been asso-
ciated with various functional effects at the myoﬁla-
ment level grandly contributing to a wide range of
clinical phenotypes such as hypertrophic cardiomy-
opathy (HCM), dilated cardiomyopathy (DCM),
restrictive cardiomyopathy (RCM), nemaline myop-
athy or Laing early onset distal myopathy.2 3 No
treatment exists for these sarcomeric diseases. The
current guidelines state that therapeutic interventions
should simply target symptoms relief.4 The present
short review article aims to brieﬂy summarise the
recent advances in our understanding of the molecu-
lar pathogenic mechanisms and the rationale for
further testing myoﬁlament-based therapeutic inter-
ventions involving the molecular motor, myosin.
SARCOMERIC MUTATIONS AND CLINICAL
PHENOTYPES
Here, the focus is on congenital cardiomyopathies
and skeletal myopathies caused by dominant inher-
ited and de novo mutations in genes encoding sarco-
meric proteins. Mutations in MYH7 and MYBPC3
encoding for β-myosin heavy chain and myosin-
binding protein C, respectively, are responsible for
more than 70% of identiﬁed cardiac cases.5 Other
genes such as MYL2, MYL3, ACTC1, TNNT2,
TNNI3, TPM1, TTN and DES are also affected but
account for less than 5% each.5 These gene defects
lead to HCM, which is associated with left ventricu-
lar hypertrophy, small cavity size and vigorous sys-
tolic function.6 They can also induce DCM, RCM
and left ventricular non-compaction cardiomyop-
athy, which are also characterised by enlarged left
ventricles but with various effects on systolic func-
tion.7–9 Skeletal muscle-related mutations have also
been identiﬁed in many genes including NEB and
ACTA1 encoding for nebulin and skeletal α-actin,
respectively, as well as TPM2, TPM3, MYH7 and
MYH2.10 11 These mutations often interfere with
the normal limb, masticatory and respiratory muscle
functioning resulting in atrophy and impairing
mobility, feeding and breathing.10 11 The following
is a non-exhaustive list of the most common dis-
eases: nemaline myopathy,11 Laing early onset distal
myopathy,12 actin myopathy,13 intranuclear rod
myopathy,13 rod-core disease,13 congenital ﬁbre-
type disproportion,13 hyaline body myopathy,12
myosin storage myopathy,12 inclusion body myop-
athy12 and myoﬁbrillar myopathy.14 Interestingly, a
few of the above mutations, especially in the MYH7
gene, are associated with cardiac and skeletal symp-
toms as the encoded protein, β/slow-cardiac myosin
is present in both cardiac and skeletal muscles.12
HYPERCONTRACTILE OR HYPOCONTRACTILE
MYOFILAMENTS
All these proteins are essential for muscle contrac-
tion. Brieﬂy, in the sarcomere, calcium ions activate
the thin ﬁlaments by directly binding to troponin
C, allowing the movement of tropomyosin mole-
cules to uncover myosin-binding sites on actin
monomers. Myosin then binds and pulls on the
thin ﬁlaments, shortening the sarcomere. Myosin
cycling is triggered by the hydrolysis of ATP into
ADP and inorganic phosphate. The release of phos-
phate is crucial for the myosin head-bending and
force generation. Subsequently, when calcium ions
are removed from the cytoplasm, the sarcomere
relaxes. Other sarcomeric proteins such as titin, the
intermediate ﬁlaments and Z-disc proteins are also
important for mechanosensing and maintaining the
sarcomeric structure during contraction.15 16 When
sarcomeric mutations occur, the genotype-
phenotype relationships become complex. Muscle
dysfunction usually depends on the mutation loca-
tion within the gene, the consequence at the
protein level and the secondary disease-related
protein post-translational modiﬁcations.2 3 Mutant
proteins or post-translational modiﬁcations of sar-
comeric proteins in the presence of mutations alter
troponin C activation, tropomyosin conformational
changes, myosin enzymatic ATPase activity, ultim-
ately altering the duty ratio, which is the fraction of
myosin heads forming strong force-generating
interactions with thin ﬁlaments at any moment.
Increasing or decreasing the duty ratio modulates
force production, shortening velocity, power output
and energy cost. Since the power output is the
product of force and velocity of muscle contrac-
tion, any modulation of force or/and velocity
would lead to an alteration in power. These
molecular alterations thus result in either myoﬁla-
ment hypercontractility or hypocontractility.3 17
In the case of HCM and DCM mutations, these
phenomena overall affect the cardiac output and
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can induce various abnormalities and remodelling in myocardial
structure and function, ultimately provoking obstruction, heart
failure and/or sudden death. For instance, M531R mutants in
the motor domain of the human β/slow-cardiac myosin mol-
ecule have been shown to be stronger motors and have been
suggested to interrupt myosin head putative interactions with
other proteins (eg, myosin-binding protein C) resulting in
hyperdynamic heart.18 In contrast to congenital cardiomyop-
athies where a vast number of mutations have hypercontractile
consequences, most of skeletal myopathies-related mutations
induce hypocontractility and overall weakness,17 19–21 with only
a few exceptions contributing to muscle stiffness and/or
hypertonia.22 23
RATIONALE FOR MYOFILAMENT-ORIENTATED THERAPIES
The current cardiac therapeutic interventions using small mole-
cules have mixed long-term improvements on muscle pathology/
remodelling or clinical outcomes. One potential explanation is
that these particular interventions do not directly target the
molecular pathogenic causes of the muscle diseases, that is,
myoﬁlament dysfunction. Hence, developing new therapies that
precisely correct for the contractile alteration may represent
novel and efﬁcacious approaches to preventing onset and pro-
gression or treating muscle pathology in the setting of inherited
cardiac and skeletal myopathies.24 25 As myoﬁlament activation
requires the calcium ions, a few positive inotropes have been
developed and subdivided into two categories, that is, calcium-
mobilising agents and calcium sensitisers.26 These drugs could
potentially increase myoﬁlament function.26 Calcium-mobilising
compounds, such as amrinone, milrinone and vesnarinone, act
as phosphodiesterase 3 (PDE3) inhibitors and favour an increase
in the amount of intracellular calcium ions released from the
sarcoplasmic reticulum. Similarly, some of the calcium sensiti-
sers, including levosimendan, a drug used in patients with heart
failure, have some PDE3 inhibitory activity, but directly bind to
troponin C, decreasing the concentration of calcium ions
required to trigger muscle contraction, increasing cardiac efﬁ-
ciency.27 This is notably the case of MCI-154, pimobendan, sul-
mazole and bepridil.28–31 The main advantage of this class of
drugs over calcium-mobilising agents is the stimulation of the
activity without increasing the cytosolic calcium concentration.
However, all the above positive inotropes have been observed to
aggravate the cardiac phenotypes and provoke arrhythmias,
hypotension and mortality in a number of heart diseases such as
HCM. A few other small molecules have speciﬁcally been devel-
oped for skeletal myopathies such as CK-2066206,
CK-2127107 or tirasemtiv.19 32 33 They speciﬁcally bind to the
fast isoform of troponin C that is only present in skeletal myoﬁ-
laments. Their clinical efﬁcacy remains uncertain as they drastic-
ally slow the rate of calcium ions dissociation from troponin C,
impairing the relaxation process.33
MYOSIN AS A PREFERENTIAL TARGET
In addition to troponin modulators, another recent experimen-
tal therapeutic approach consists of ﬁne-tuning myosin function
(table 1). The research compounds CGP-48506 and
EMD-57033 directly affect myosin activity and the duty
ratio19 34–36 but have been observed to be toxic. Omecamtiv
mecarbil, on the other hand, has a potential for therapeutic
application.37 This strong positive inotropic small molecule
binds directly to cardiac myosin and acts as an allosteric effector
to enhance myosin motor activity and cardiac performance
without increasing the intracellular calcium concentration.37
Omecamtiv mecarbil shifts the equilibrium of the myosin
ATPase hydrolysis cycle towards products by accelerating phos-
phate release and leads to a faster transient from weak to strong
actin-bound states38 (ﬁgure 1). Therefore, this drug exhibits the
positive inotropic effects by increasing the duty ratio of myosin
motor. In the heart, it prolongs the systolic ejection time
without any increase in the rate of pressure development or
myocardial oxygen demand. This shortens the diastolic ﬁlling
time resulting in reduced coronary blood ﬂow and risks of
ischaemia. Clinical trials are encouraging and oral omecamtiv
mecarbil could potentially be beneﬁcial in the context of DCM
and RCM where sarcomeric mutations reduce the myosin duty
ratio. For HCM, negative inotropic agents are likely to have
positive effects. Research molecules including blebbistatin and
2,3-butanedione monoxime have been developed and found to
inhibit myosin activity by stabilising the myosin converter
domain in a relaxed conformation, inducing a slowing of phos-
phate release and a decreasing in the duty ratio.39 40
Unfortunately, the toxicity of these small compounds is quite
high.24 Recently, a small molecule, MYK-461, which also inter-
feres with the phosphate release step of the myosin ATPase
cycle, has been shown the potential of therapeutic approach for
HCM. MYK-461 inhibits cardiac myosin ATPase by slowing
Table 1 Experimental approaches targeting myosin (derived from Ref. 24)
Approach Compound Target Function
Pharmacological Blebbistatin (research tool only) Myosin class II
All heavy chain isoforms
Inhibitor
N-benzyl-p-toluene sulphonamide (research tool only) Myosin class II
Fast-skeletal heavy chain isoform
Inhibitor
2,3-butanedione monoxime (research tool only) Myosin class II
All heavy chain isoforms
Inhibitor
MYK-461 (preclinical—MyoKardia) Myosin class II
ß/slow-cardiac heavy chain isoform
Inhibitor
Omecamtiv Mecarbil (clinical trial—Cytokinetics) Myosin class II
ß/slow-cardiac heavy chain isoform
Activator
CGP48506 (preclinical—Novartis) Myosin class II
ß/slow-cardiac heavy chain isoform
Activator
EMD57033 (preclinical—Merck) Myosin class II
ß/slow-cardiac heavy chain isoform
Activator
Genetic MYL4 incorporation (preclinical) Myosin class II
Atrial/fetal essential light chain isoform
Activator
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phosphate release and, consequently, reduces the myosin duty
ratio and power output (ﬁgure 1). Tests on transgenic mice
mimicking HCM and expressing particular mutations in the
gene encoding for β-myosin heavy chain (leading to point sub-
stitutions: R403Q, R719W and R453C) demonstrate that
MYK-461 reduces cardiac contractility and, when administered
early in the course of the disease, it blunts the development of
left ventricular hypertrophy.41 These phenomena are cardiac-
speciﬁc and MYK-461 has no impact on skeletal muscle
function.41
Modulating the activation of myosin molecules in the context
of skeletal myopathies can be achieved using gene therapy. Each
myosin molecule is composed of two regulatory and two essen-
tial/alkali light chains.42 These latter are regulating the duty
ratio,42 with some of the isoforms being very efﬁcient force gen-
erators. This is speciﬁcally the case of the isoform encoded by
the MYL4 gene and only present in the heart and skeletal
muscles from embryos.42 By implementing this isoform in the
skeletal muscles of mice carrying one speciﬁc mutation in the
ACTA1 gene encoding for skeletal α-actin (H40Y replacement),
myosin activity is enhanced and myoﬁbres recover their force
production, avoiding the development of muscle atrophy.43
CONCLUSION
By alleviating muscle pathology, myosin activators and inhibitors
represent promising new drug targets. Indeed, at the molecular
level, these modify the ATPase activity, phosphate release,
myosin-binding state and duty ratio, which are essential for
regulating the force generation.
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